• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

下肢痉挛接受常规肉毒毒素治疗的患者的临床表现:一项国际观察性研究的基线结果。

Clinical presentation of patients with lower limb spasticity undergoing routine treatment with botulinum toxin: baseline findings from an international observational study.

机构信息

MossRehab Jefferson Health, Elkins Park, PA, USA.

MedStar National Rehabilitation Network and Georgetown University School of Medicine, Washington, DC, USA.

出版信息

J Rehabil Med. 2023 Oct 5;55:jrm4257. doi: 10.2340/jrm.v55.4257.

DOI:10.2340/jrm.v55.4257
PMID:37794845
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10562995/
Abstract

OBJECTIVE

Describe how people with lower limb spasticity present for treatment in routine clinical practice.

METHODS

Prospective, observational study (Clinicaltrials.gov: NCT04050527) of ambulatory adult patients (≥ 18 years) with unilateral lower limb spasticity (able to take ≥ 5 steps with or without assistance) presenting for routine spasticity management, including treatment with abobotulinumtoxinA.

RESULTS

The study population included 430 adults with lower limb spasticity. Despite their relatively young age (mean ± standard deviation 53.7 ± 13.9 years), only 20% of patients were employed. Most patients had an acquired brain injury due to cerebrovascular disease; 84.1% reported having concomitant upper limb spasticity. Using the Leg Activity Measure, most patients reported no or only mild difficulties in performing hygiene/positioning tasks, while 80.7% had at least mild difficulty with indoor ambulation and 90.5% had at least mild difficulty with walking outdoors. Sensory, communication and/or cognitive impairments were also common. At the first treatment cycle, 50.7% of patients set active function primary goals, including locomotion transferring or standing.

CONCLUSION

These observations highlight the complexity of presentation that must be considered when setting treatment goals for lower limb spasticity and emphasize the types of impairment and activity (functional) limitations that treating teams may expect to encounter in their patients and should cover in their initial and follow-up assessments.

摘要

目的

描述在常规临床实践中下肢痉挛患者的就诊情况。

方法

前瞻性、观察性研究(Clinicaltrials.gov:NCT04050527)纳入了 430 名单侧下肢痉挛(能独立或辅助行走≥5 步)的门诊成年患者(≥18 岁),这些患者存在下肢痉挛,正在接受常规痉挛管理,包括接受阿博特利珠单抗治疗。

结果

研究人群包括 430 名下肢痉挛患者。尽管他们相对年轻(平均±标准差 53.7±13.9 岁),但只有 20%的患者有工作。大多数患者因脑血管病而患有获得性脑损伤;84.1%的患者报告同时存在上肢痉挛。使用下肢活动测量量表,大多数患者报告在进行个人卫生/体位转换任务时无困难或仅存在轻度困难,而 80.7%的患者在室内行走至少存在轻度困难,90.5%的患者在户外行走至少存在轻度困难。感觉、沟通和/或认知障碍也很常见。在第一个治疗周期中,50.7%的患者设定了主动功能的主要目标,包括转移或站立行走。

结论

这些观察结果强调了在为下肢痉挛设定治疗目标时必须考虑的就诊复杂性,并强调了治疗团队在患者中可能遇到的损害类型和活动(功能)受限,这些内容应在他们的初始和随访评估中涵盖。

相似文献

1
Clinical presentation of patients with lower limb spasticity undergoing routine treatment with botulinum toxin: baseline findings from an international observational study.下肢痉挛接受常规肉毒毒素治疗的患者的临床表现:一项国际观察性研究的基线结果。
J Rehabil Med. 2023 Oct 5;55:jrm4257. doi: 10.2340/jrm.v55.4257.
2
BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.BoTULS 研究:一项多中心随机对照试验,旨在评估 A 型肉毒毒素治疗脑卒中后上肢痉挛的临床疗效和成本效益。
Health Technol Assess. 2010 May;14(26):1-113, iii-iv. doi: 10.3310/hta14260.
3
[Impact of integrated upper limb spasticity management including repeat botulinum toxin type A (BoNT-A) injections on patient-centred goal attainment in real-life practice: results from the prospective, observational Upper Limb International Spasticity cohort study (ULIS-III) in a Russian subpopulation].[包括重复注射A型肉毒杆菌毒素(BoNT-A)在内的上肢痉挛综合管理对现实生活中以患者为中心的目标达成情况的影响:俄罗斯亚人群前瞻性观察性上肢国际痉挛队列研究(ULIS-III)的结果]
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(11):39-48. doi: 10.17116/jnevro202112111139.
4
Botulinum Toxin Type A Improves Function According to Goal Attainment in Adults with Poststroke Lower Limb Spasticity in Real Life Practice.A型肉毒毒素在真实生活实践中改善了成人卒中后下肢痉挛患者的功能,依据目标实现情况而定。
Eur Neurol. 2019;82(1-3):1-8. doi: 10.1159/000503172. Epub 2019 Nov 14.
5
More than a black box of rehabilitation: Characterizing therapy programmes following botulinum toxin injections for spasticity in adults with stroke.不仅仅是康复的黑箱:中风后成人痉挛性肉毒杆菌毒素注射治疗方案的特征分析
J Rehabil Med. 2016 Apr 28;48(5):426-34. doi: 10.2340/16501977-2085.
6
[Treatment goals in patients with post-stroke upper limb spasticity following injection of botulinum toxin A : Results of the German-Austrian subgroup of the ULIS-II study].[注射A型肉毒杆菌毒素后中风后上肢痉挛患者的治疗目标:ULIS-II研究的德奥亚组结果]
Nervenarzt. 2019 Apr;90(4):361-370. doi: 10.1007/s00115-018-0630-1.
7
Impact of integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: rationale and protocol for an international prospective, longitudinal cohort study (ULIS-III).包括A型肉毒毒素在内的上肢痉挛综合管理对以患者为中心的目标达成的影响:一项国际前瞻性纵向队列研究(ULIS-III)的原理与方案
BMJ Open. 2016 Jun 17;6(6):e011157. doi: 10.1136/bmjopen-2016-011157.
8
Evaluating the functional outcomes of ultrasound-guided botulinum toxin type A injections using the Euro-musculus approach for upper limb spasticity treatment in post-stroke patients: an observational study.采用 Euro-musculus 方法评估超声引导肉毒毒素 A 注射治疗脑卒中后上肢痉挛患者的功能结局:一项观察性研究。
Eur J Phys Rehabil Med. 2018 Oct;54(5):738-744. doi: 10.23736/S1973-9087.18.05086-4. Epub 2018 Feb 7.
9
Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study.包括重复注射A型肉毒杆菌毒素在内的上肢痉挛综合管理的纵向目标达成情况:前瞻性观察性上肢国际痉挛(ULIS-III)队列研究的结果
J Rehabil Med. 2021 Feb 24;53(2):jrm00157. doi: 10.2340/16501977-2801.
10
Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III Study.采用结构化的目标设定和结果测量方法评估上肢痉挛管理的效果:ULIS-III 研究的第一周期结果。
J Rehabil Med. 2021 Jan 1;53(1):jrm00133. doi: 10.2340/16501977-2770.

引用本文的文献

1
The Impact of Strength Changes on Active Function Following Botulinum Neurotoxin-A (BoNT-A): A Systematic Review.肉毒杆菌神经毒素A(BoNT-A)注射后力量变化对主动功能的影响:一项系统评价
Toxins (Basel). 2025 Jul 23;17(8):362. doi: 10.3390/toxins17080362.
2
Switox: Retrospective Analysis of Botulinum Toxin Switching in Management of Spasticity.Switox:痉挛管理中肉毒杆菌毒素转换的回顾性分析。
Toxins (Basel). 2025 Feb 24;17(3):103. doi: 10.3390/toxins17030103.
3
Muscle selection and dosing in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in real-world practice.

本文引用的文献

1
European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A.欧洲专家共识:改善鞘内注射巴氯芬和/或肉毒毒素 A 治疗致残性痉挛患者选择的方法。
J Rehabil Med. 2022 Jan 3;54:jrm00241. doi: 10.2340/16501977-2877.
2
Framework for the treatment and reporting of missing data in observational studies: The Treatment And Reporting of Missing data in Observational Studies framework.观察性研究中缺失数据的处理和报告框架:观察性研究中缺失数据的处理和报告框架。
J Clin Epidemiol. 2021 Jun;134:79-88. doi: 10.1016/j.jclinepi.2021.01.008. Epub 2021 Feb 2.
3
在现实临床实践中,接受阿柏西普肉毒素A治疗下肢痉挛的患者的肌肉选择和剂量确定
J Rehabil Med. 2025 Feb 7;57:jrm42605. doi: 10.2340/jrm.v57.42605.
4
Efficacy of botulinum toxin A combined with extracorporeal shockwave therapy in post-stroke spasticity: a systematic review.A型肉毒毒素联合体外冲击波疗法治疗脑卒中后痉挛的疗效:一项系统评价
Front Neurol. 2024 Mar 15;15:1342545. doi: 10.3389/fneur.2024.1342545. eCollection 2024.
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
204 个国家和地区 1990-2019 年 369 种疾病和伤害导致的全球负担:2019 年全球疾病负担研究的系统分析。
Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9.
4
A synthesis and appraisal of clinical practice guidelines, consensus statements and Cochrane systematic reviews for the management of focal spasticity in adults and children.成人和儿童局灶性痉挛管理的临床实践指南、共识声明和 Cochrane 系统评价的综合评价。
Disabil Rehabil. 2022 Feb;44(4):509-519. doi: 10.1080/09638288.2020.1769207. Epub 2020 Jun 5.
5
Psychometric evaluation of the leg activity measure (LegA) for outcome measurement in people with brain injury and spasticity.脑损伤伴痉挛患者结局测量用腿部活动测量量表(LegA)的心理测量学评估。
Disabil Rehabil. 2021 Apr;43(7):976-987. doi: 10.1080/09638288.2019.1643933. Epub 2019 Jul 22.
6
Categorisation of goals set using Goal Attainment Scaling for treatment of leg spasticity: a multicentre analysis.使用目标达成量表对腿部痉挛治疗目标进行分类:一项多中心分析。
Disabil Rehabil. 2019 Aug;41(16):1925-1930. doi: 10.1080/09638288.2018.1451927. Epub 2018 Mar 20.
7
A systematic review: efficacy of botulinum toxin in walking and quality of life in post-stroke lower limb spasticity.系统评价:肉毒毒素治疗脑卒中后下肢痉挛性步行和生活质量的疗效。
Syst Rev. 2018 Jan 5;7(1):1. doi: 10.1186/s13643-017-0670-9.
8
A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework.成人痉挛性弛缓的全面以患者为中心方法:基于共识的框架。
Eur J Phys Rehabil Med. 2018 Aug;54(4):605-617. doi: 10.23736/S1973-9087.17.04808-0. Epub 2017 Dec 21.
9
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.实践指南更新摘要:肉毒杆菌神经毒素用于治疗眼睑痉挛、颈部肌张力障碍、成人痉挛和头痛:美国神经病学学会指南制定小组委员会报告
Neurology. 2016 May 10;86(19):1818-26. doi: 10.1212/WNL.0000000000002560. Epub 2016 Apr 18.
10
Gait Speed Predicts Incident Disability: A Pooled Analysis.步速可预测新发残疾:一项汇总分析。
J Gerontol A Biol Sci Med Sci. 2016 Jan;71(1):63-71. doi: 10.1093/gerona/glv126. Epub 2015 Aug 22.